Clinical Trials Directory

Trials / Completed

CompletedNCT04987606

Post COVID-19 Interstitial Lung Disease: A Study of Genetic and Environmental Interactions

POST COvid-19 Interstitial Lung DiseasE (POSTCODE) A Study of Genetic and Environmental Interactions: an Observational Cohort Study.

Status
Completed
Phase
Study type
Observational
Enrollment
40 (actual)
Sponsor
Imperial College London · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Not accepted

Summary

This study aims to understand why some people who have had COVID-19 develop scarring of the lungs and why some people recover more quickly than others.

Detailed description

A large number of people diagnosed with COVID-19 suffer from long term symptoms, predominantly breathlessness and fatigue whether or not they were admitted to hospital. While there are a number of causes of long-term breathlessness following COVID-19 one of the most common, and potentially concerning with regards to long term prognosis is Interstitial Lung Disease. The fibrogenic potential of SARS-CoV-2 is currently unknown but is predicted to be substantial based on the experience of previous coronavirus outbreaks and emerging data from this pandemic. The investigators do not yet understand how scarring occurs following SARS-CoV-2, nor why there is resolution in some individuals and persistent or progressive disease in others. The investigators therefore plan to undertake bronchoscopy (camera test into the lungs) to examine for changes in the way the cells lining the lung behave, using genetics, and differences in the bacteria living in the airways in patients whom have developed scarring following COVID-19.

Conditions

Timeline

Start date
2021-07-01
Primary completion
2023-04-01
Completion
2024-04-01
First posted
2021-08-03
Last updated
2024-04-18

Locations

4 sites across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT04987606. Inclusion in this directory is not an endorsement.